Posts

Posted on

Aptiv to Present at the Barclays Global Automotive Conference

PR Newswire

DUBLIN, Nov. 13, 2020 /PRNewswire/ — Aptiv PLC (NYSE: APTV), a global technology company focused on making mobility safer, greener, and more connected, will present at the Barclays Global Automotive Conference. Aptiv’s President and Chief Executive Officer, Kevin Clark, and Chief Financial Officer and Senior Vice President, Business Operations, Joseph Massaro, will present on Thursday, November 19 at 12:10 p.m. EST.

A simultaneous webcast of the presentation will be available on the Aptiv Investor Relations website at ir.aptiv.com. For additional information, please contact Aptiv Investor Relations at [email protected].

About Aptiv
Aptiv is a global technology company that develops safer, greener and more connected solutions enabling the future of mobility. Visit aptiv.com.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/aptiv-to-present-at-the-barclays-global-automotive-conference-301172998.html

SOURCE Aptiv PLC

Posted on

BeyondSpring to Present Corporate Overview at Jefferies London Healthcare Conference

NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) — BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medical needs, today announced that management will provide a corporate overview at the Jefferies London Healthcare Conference on November 17th. Details are as follows:



Jefferies London Healthcare Conference (Presentation)
   
Date:                         Tuesday, November 17
Time:                         2:55 pm Eastern Time
Webcast:          Click here to view webcast

The presentation will be webcast live and archived on BeyondSpring’s website at www.beyondspringpharma.com under “Events & Presentation” in the Investors section.

About BeyondSpring

Headquartered in New York, BeyondSpring is a global, clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to improve clinical outcomes for patients with high unmet medical needs. BeyondSpring’s first-in-class lead immune asset, Plinabulin, is a potent antigen-presenting cell (APC) inducer. It is currently in two Phase 3 clinical trials for two severely unmet medical needs indications: one in combination with pegfilgrastim for the prevention of chemotherapy-induced neutropenia (CIN), the most frequent cause for a chemotherapy regimen dose’s decrease, delay, downgrade or discontinuation, which can lead to suboptimal clinical outcomes. The Plinabulin and G-CSF combination regimen received breakthrough Therapy Designation from US FDA and China NMPA for the CIN indication. The other for non-small cell lung cancer (NSCLC) treatment in EGFR wild-type patients. As a “pipeline drug,” Plinabulin is in various I/O combination studies to boost PD-1 / PD-L1 antibody anti-cancer effects. In addition to Plinabulin, BeyondSpring’s extensive pipeline includes three pre-clinical immuno-oncology assets.  Its subsidiary Seed Therapeutics has a proprietary drug discovery platform dubbed “molecular glue” that uses the protein degradation pathway, for which Seed has a collaboration with Eli Lilly. 

Investor Contact:

Ashley Robinson
LifeSci Advisors
[email protected]
617-430-7577

Media Contact:

Darren Opland, Ph.D.
LifeSci Communications
[email protected]
646-627-8387



Posted on

Elah Holdings, Inc. Releases Third Quarter 2020 Report to Stockholders

Financial Statements for Q3 2020

PR Newswire

DALLAS, Nov. 13, 2020 /PRNewswire/ — Elah Holdings, Inc. (OTC:ELLH) has released its interim unaudited report for the third quarter of 2020. This report and additional company information can be found at www.elahholdings.com under the Financial Releases section of the website.

About Elah Holdings
Elah Holdings, Inc. (formerly known as Real Industry, Inc.) is a reorganized holding company led by experienced business leaders that is seeking to acquire profitable businesses in the commercial and industrial markets to generate sustainable profitability and cash flows, unlock the value of our considerable tax assets, and use creative deal structures that reduce risk and ultimately create long-term value for our shareholders. For more information, visit www.elahholdings.com. Elah Holdings’ stock trades on the OTC Pink Market, which is operated by OTC Markets Group, a centralized electronic quotation service for over-the-counter securities under the symbol “ELLH.”

Contact:


Michael Hobey

Elah Holdings, Inc.

+1 (805) 435-1255

@elah_inc


www.linkedin.com/company/elah-holdings-inc/

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/elah-holdings-inc-releases-third-quarter-2020-report-to-stockholders-301173000.html

SOURCE Elah Holdings, Inc.

Posted on

Brownie’s Marine Group Announces New Chief Executive Officer

Pompano Beach, Florida, Nov. 13, 2020 (GLOBE NEWSWIRE) — Brownies Marine Group, Inc. (OTCQB: BWMG), a leading developer, manufacturer and distributor of tankless dive equipment and high pressure air and industrial compressors in the marine industry, announces today that Mr. Christopher Constable has been named a Chief Executive Officer of the public company, while Mr. Robert Carmichael will remain Chairman, and President of the Company. Mr. Constable has also been appointed to the Board of Directors of BWMG.

Robert Carmichael, Chairman and President, stated, “Chris was brought in earlier this year on a consulting basis, and has done a great job for us. As we move the Company to the next stage of growth with our different business units, we feel his numerous operating and financial skill sets can help to get us there faster.”

“I’m impressed with what Robert and the rest of the team have been able to accomplish to date. This Company is building some of the coolest and best engineered products in the marine industry.” Christopher Constable, Chief Executive Officer of BWMG stated. “I cannot possibly replace the knowledge and experience that Robert brings to the Company, and I look forward to working side by side with him as he uses his unique skill set to dive into special projects aimed at growing revenue across all business lines. We have a few specific goals that we are laser focused on, including growing top line, improving operations using a data driven decision making process, leading a systematic M&A process, and driving shareholder value through communicating those efforts to investors.”

Mr. Constable’s previous experiences included several operating and financial roles, including being the Former Chief Financial Officer of Blue Star Foods Corp. (OTCPK:BSFC), and a consultant at Gateway Capital Corp. where he working with companies to improve their financial performance and with lenders to analyze the financial and reporting capabilities of prospective lending customers. He began his career in commercial banking where he worked for banking institutions in Maryland and Florida in multiple capacities in commercial lending. Mr. Constable received his BS in Finance with an Accounting Minor from the Merrick School of Business at the University of Baltimore.

About Brownie’s Marine Group

Brownie’s Marine Group, Inc., is the parent company to a family of innovative brands with a unique concentration in the industrial and recreational diving industry. The Company, together with its subsidiaries, designs, tests, manufactures, and distributes recreational hookah diving, yacht-based scuba air compressors and nitrox generation systems, and scuba and water safety products in the United States and internationally. The Company has three subsidiaries: Trebor Industries, Inc., founded in 1981, dba as “Brownie’s Third Lung”; BLU3, Inc.; and Brownie’s High-Pressure Services, Inc., dba LW Americas. The Company is headquartered in Pompano Beach, Florida.

For more information, visit: www.BrowniesMarineGroup.com.

Safe Harbor Statement

This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors. Stockholders and potential investors should not place undue reliance on these forward-looking statements. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements in this report are reasonable, we cannot assure stockholders and potential investors that these plans, intentions or expectations will be achieved. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission (the “SEC”) on June 29, 2020 and our other periodic and quarterly filings with the SEC.

Source: Brownie’s Marine Group, Inc.
Contact Information: (954)-462-5570
[email protected]



Posted on

Farmers & Merchants Bancorp, Inc. Announces Office Realignment

Consolidation Part of Strategic Plan and Continued Investments in Remote and Electronic banking to Enhance Customer Banking Experience

ARCHBOLD, Ohio, Nov. 13, 2020 (GLOBE NEWSWIRE) — Farmers & Merchants Bancorp, Inc. (Nasdaq: FMAO) today announced plans to consolidate four of its offices as part of the Company’s strategic plan to improve operating efficiencies, reinvest in new remote and electronic banking initiatives, and better serve customers.

Lars B. Eller, President and Chief Executive Officer, stated: “Our customers have come to expect the best and easiest banking experience from us, and we continue to work hard to deliver on that expectation. Over the years, we have continued to allocate resources into developing ways to bank with us electronically and remotely. Our customers are using these products and services more and more every day, including during the limited access of in-lobby banking that occurred earlier this year as a result of the COVID-19 pandemic.”

F&M’s office realignment plans include:

  • 1313 S. Defiance St., Archbold,
    OH office will consolidate into our Archbold Main Office at 307 N. Defiance Street effective March 1, 2021 and reopen drive-up services at our Archbold Operations Center at 620 S. Clyde’s Way.
  • 119 N. Fulton St., Wauseon,
    OH office will consolidate into our Wauseon Shoop Office, 1130 N. Shoop Avenue effective March 1, 2021.
  • 929 E. High St., Bryan,
    OH office will consolidate into our Bryan South Towne Office, 1000 S. Main St effective March 1, 2021. The Bryan East High Office will temporarily provide limited access to drive-up services and appointment only services as F&M expands its Bryan South Towne Office.
  • 103 Main St., Monroeville, IN will consolidate into our Decatur Office, 1118 S. 13th St. effective March 1, 2021. F&M also has two additional full-service locations in Allen County, our NEW Fort Wayne Illinois Road Office, 7370 Illinois Rd. and our Huntertown Office, 12106 Lima Rd.
  • F&M will continue to operate ATMs at all impacted locations

Additional information relating to the closures will be sent to the customers that bank at these offices in the next few days. In addition, customers with safe deposit boxes at the effected offices will receive detailed information on how to transfer the contents within the next 30 days. Customers with any questions or concerns, please call F&M at 419-446-2501. Employees impacted by F&M’s office consolidation program will have opportunities to transition to other roles within F&M over the course of the next few months.

Mr. Eller continued: “Consolidating offices is a challenging but necessary decision and follows a thorough review of our operations. Having a physical presence in our markets remains an important component of our community-oriented values and the locations we are closing are all conveniently located near other F&M offices. In addition, the added ease of being able to bank with F&M in various ways has reduced the usage of some of our office locations. As a result, we want to continue to meet our goal of delivering the best products, services, and customer experience to our communities and will redirect resources to support our remote and electronic banking platform.”

“We are working closely with affected employees to help them transition to other roles within F&M. Over the past 12 months, we have added new loan production offices in Muncie, IN and Oxford, OH. In addition, a new loan production office in West Bloomfield, MI and a new full-service branch in Fort Wayne are expected to open in the coming weeks. Our expansion strategy is adding high-quality jobs within our communities and I am encouraged with our ability to attract experienced, motivated, and dedicated associates to the F&M team. For offices impacted by our consolidation plans, we are working on opportunities that we believe will enable continued contributions to our communities,” concluded Mr. Eller.

About Farmers & Merchants State Bank:

The Farmers & Merchants State Bank is a local independent community bank that has been serving Northwest Ohio and Northeast Indiana since 1897. The Farmers & Merchants State Bank provides commercial banking, retail banking and other financial services through its offices. Our locations are in Fulton, Defiance, Hancock, Henry, Lucas, Williams, and Wood counties in Northwest Ohio. In Northeast Indiana, we have offices located in Adams, Allen, DeKalb, Jay, and Steuben counties.

Safe harbor statement

Farmers & Merchants Bancorp, Inc. (“F&M”) wishes to take advantage of the Safe Harbor provisions included in the Private Securities Litigation Reform Act of 1995. Statements by F&M, including management’s expectations and comments, may not be based on historical facts and are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21B of the Securities Exchange Act of 1934, as amended. Actual results could vary materially depending on risks and uncertainties inherent in general and local banking conditions, competitive factors specific to markets in which F&M and its subsidiaries operate, future interest rate levels, legislative and regulatory decisions, capital market conditions, or the effects of the COVID-19 pandemic, and its impacts on our credit quality and business operations, as well as its impact on general economic and financial market conditions. F&M assumes no responsibility to update this information. For more details, please refer to F&M’s SEC filing, including its most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Such filings can be viewed at the SEC’s website, www.sec.gov or through F&M’s website www.fm.bank.

Company Contact: Investor and Media Contact:
Lars B. Eller
President and Chief Executive Officer
Farmers & Merchants Bancorp, Inc.
(419) 446-2501
[email protected]		 Andrew M. Berger
Managing Director
SM Berger & Company, Inc.
(216) 464-6400
[email protected]



Posted on

RAVE Restaurant Group, Inc. Reports First Quarter Financial Results

PR Newswire

DALLAS, Nov. 13, 2020 /PRNewswire/ — RAVE Restaurant Group, Inc. (NASDAQ: RAVE) today reported financial results for the first quarter ended September 27, 2020.

First
 Quarter Highlights:

  • The Company recorded net income of $76 thousand for the first quarter of fiscal 2021 compared to net income of $237 thousand for the same period of the prior year.
  • Total revenue decreased by $1.0 million to $1.9 million for the first quarter of fiscal 2021 compared to the same period of the prior year.
  • Income before taxes was $78 thousand for the first quarter of fiscal 2021 compared to $310 thousand for the same period of the prior year.
  • Pizza Inn domestic comparable store retail sales decreased 22% in the first quarter of fiscal 2021 compared to the same period of the prior year.
  • Pie Five comparable store retail sales decreased 23% in the first quarter of fiscal 2021 compared to the same period of the prior year.
  • On a fully diluted basis, net income decreased $0.01 per share to $0.00 per share for the first quarter of fiscal 2021 compared to net income of $0.01 per share for the same period of the prior year.
  • Cash and cash equivalents decreased $33 thousand during the first quarter of fiscal 2021 to $2.9 million at September 27, 2020.
  • Pizza Inn domestic unit count finished at 146.
  • Pizza Inn international unit count finished at 32.
  • Pie Five domestic unit count finished at 39.

“We continue to work through challenges presented by the global health crisis, but we will not be sidelined by the pandemic and are resolute in repositioning RAVE for long-term success,” said Brandon Solano, Chief Executive Officer of RAVE Restaurant Group, Inc.  “Safety for our customers remains our top priority and our first quarter results demonstrate that the coordinated response from our franchisees and restaurant support team continues to drive traffic and incremental sales despite operating challenges.”

“At Pizza Inn, we created the Contactless Buffet To-Go to maximize value and variety for guests and to lower the impact of reduced foot traffic,” Solano said.  “We recently brought back the Contactless Buffett To-Go with three new value-oriented options and along with our New Right-Way Buffet, we are seeing impressive results in driving traffic and ticket average.”

“At Pie Five, we are continuing to test menu upgrades and look forward to rolling out several new options soon,” said Solano.  “We are also continuing to leverage the Circle of Crust rewards program and are seeing a steady return in traffic along with positive sales trends with third-party delivery utilization.”

“Income before taxes of $78 thousand is an encouraging start for the first quarter of fiscal 2021 and demonstrates our commitment to controlling costs amid revenue declines,” said Clint Fendley, Vice President of Finance of RAVE Restaurant Group, Inc.   “RAVE’s cash balance of $2.9 million at September 27, 2020, coupled with $3.8 million of gross proceeds from sales of common stock subsequent to the first quarter, reinforces our position as we continue to confront near-term uncertainty in our industry.”  

Non-GAAP Financial Measures

The Company’s financial statements are prepared in accordance with United States generally accepted accounting principles (“GAAP”). However, the Company also presents and discusses certain non-GAAP financial measures that it believes are useful to investors as measures of operating performance. Management may also use such non-GAAP financial measures in evaluating the effectiveness of business strategies and for planning and budgeting purposes. However, these non-GAAP financial measures should not be viewed as an alternative or substitute for its financial statements prepared in accordance with generally accepted accounting principles. 

The Company considers EBITDA and Adjusted EBITDA to be important supplemental measures of operating performance that are commonly used by securities analysts, investors and other parties interested in our industry. The Company believes that EBITDA is helpful to investors in evaluating its results of operations without the impact of expenses affected by financing methods, accounting methods and the tax environment. The Company believes that Adjusted EBITDA provides additional useful information to investors by excluding non-operational or non-recurring expenses to provide a measure of operating performance that is more comparable from period to period. Management also uses these non-GAAP financial measures for evaluating operating performance, assessing the effectiveness of business strategies, projecting future capital needs, budgeting and other planning purposes.

“EBITDA” represents earnings before interest, taxes, depreciation and amortization. Adjusted EBITDA represents earnings before interest, taxes, depreciation and amortization, gain/loss sale of assets, costs related to impairment, closed and non-operating store costs. A reconciliation of these non-GAAP financial measures to net income is included with the accompanying financial statements. 

Note Regarding Forward Looking Statements

Certain statements in this press release, other than historical information, may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and are intended to be covered by the safe harbors created thereby. These forward-looking statements are based on current expectations that involve numerous risks, uncertainties and assumptions. Assumptions relating to these forward-looking statements involve judgments with respect to, among other things, future economic, competitive and market conditions, regulatory framework and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of RAVE Restaurant Group, Inc. Although the assumptions underlying these forward-looking statements are believed to be reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that any forward-looking statements will prove to be accurate. In light of the significant uncertainties inherent in these forward-looking statements, the inclusion of such information should not be regarded as a representation that the objectives and plans of RAVE Restaurant Group, Inc. will be achieved. 

About RAVE Restaurant Group, Inc.

Founded in 1958, Dallas-based RAVE Restaurant Group [NASDAQ: RAVE] owns, operates, franchises and/or licenses 217 Pie Five Pizza Co. and Pizza Inn restaurants and Pizza Inn Express kiosks domestically and internationally. Pizza Inn is an international chain featuring freshly made pizzas, along with salads, pastas, and desserts. Pie Five Pizza Co. is a leader in the rapidly growing fast-casual pizza space. Pizza Inn Express, or PIE, is developing unique opportunities to provide freshly made pizza from non-traditional outlets. The Company’s common stock is listed on the Nasdaq Capital Market under the symbol “RAVE”. For more information, please visit www.raverg.com.

Contact:

Investor Relations
RAVE Restaurant Group, Inc.
469-384-5000

 


RAVE RESTAURANT GROUP, INC.


CONSOLIDATED STATEMENTS OF OPERATIONS



(In thousands, except per share amounts)


Three Months Ended


September 27,


September 29,


2020


2019


REVENUES:

$             1,903

$            2,876


COSTS AND EXPENSES:

Cost of sales

78

134

General and administrative expenses

1,089

1,363

Franchise expenses

547

866

Gain on sale of assets

–

(11)

Impairment of long-lived assets and other lease charges

17

148

Bad debt expense (recovery)

27

(8)

Interest expense

23

27

Depreciation and amortization expense

44

47

Total costs and expenses

1,825

2,566


INCOME BEFORE TAXES

78

310

Income tax expense

2

73


NET INCOME

76

237


INCOME PER SHARE OF COMMON STOCK – BASIC:

$               0.00

$              0.02


INCOME PER SHARE OF COMMON STOCK – DILUTED:

$               0.00

$              0.01


Weighted average common shares outstanding – basic

15,451

15,106


Weighted average common and


potential dilutive common shares outstanding

16,249

15,924

 


RAVE RESTAURANT GROUP, INC.


CONSOLIDATED BALANCE SHEETS



(In thousands, except share amounts)


September 27,


June 28,


2020


2020


ASSETS

CURRENT ASSETS

   Cash and cash equivalents

$       2,936

$       2,969

   Restricted cash

234

234

   Accounts receivable, less allowance for bad debts
of $77 and $269, respectively

1,012

965

   Notes receivable

484

546

   Deferred contract charges

36

44

   Prepaid expenses and other

218

174

        Total current assets

4,920

4,932

LONG-TERM ASSETS

   Property, plant and equipment, net

358

366

   Operating lease right of use asset, net

3,421

3,567

   Intangible assets definite-lived, net

146

155

   Notes receivable, net of current portion

445

449

   Long-term deferred contract charges

242

231

   Deposits and other

–

5

     Total assets

$       9,532

$       9,705


LIABILITIES AND SHAREHOLDERS’ EQUITY

CURRENT LIABILITIES

   Accounts payable – trade

$          469

$          446

   Accounts payable – lease termination impairments

421

407

   Accrued expenses

685

775

   Operating lease liability, current

644

632

   Deferred revenues

293

254

     Total current liabilities

2,512

2,514

LONG-TERM LIABILITIES

   Convertible notes

1,556

1,549

   PPP loan

657

657

   Operating lease liability, net of current portion

3,307

3,471

   Deferred revenues, net of current portion

873

960

   Other long-term liabilities

51

51

     Total liabilities

8,956

9,202

SHAREHOLDERS’ EQUITY

   Common stock, $.01 par value; authorized 26,000,000
shares; issued 22,550,376 and 22,550,376  shares, respectively;
outstanding 15,465,222 and 15,465,222 shares, respectively

225

225

   Additional paid-in capital

33,528

33,531

   Accumulated deficit

(8,640)

(8,716)

   Treasury stock at cost

     Shares in treasury: 7,085,154 and 7,085,154, respectively

-24,537

-24,537

        Total shareholders’ equity

576

503

        Total liabilities and shareholders’ equity

$       9,532

$       9,705

 


RAVE RESTAURANT GROUP, INC.


CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS



(In thousands)



(Unaudited)


Three Months Ended


September 27,


September 29,


2020


2019


CASH FLOWS FROM OPERATING ACTIVITIES:

Net income 

$                    76

$                  237

Adjustments to reconcile net income to cash
(used in) provided by operating activities:

Impairment of fixed assets and other assets

17

148

Depreciation and amortization

44

47

Amortization of operating right of use assets

146

115

Amortization of debt issue costs

7

9

Gain on the sale of assets

–

(11)

Provision for bad debt 

27

(8)

Deferred income tax

–

71

Changes in operating assets and liabilities:

Accounts receivable

(74)

272

Notes receivable

62

–

Deferred contract charges

(3)

(3)

Inventories

–

1

Prepaid expenses and other

(44)

46

Deposits and other

5

1

Accounts payable – trade

23

(110)

Accounts payable – lease termination impairments

(3)

(373)

Accrued expenses

(90)

(47)

Operating lease liability

(152)

(120)

Deferred revenue

(48)

(122)

Deferred rent and other

–

(21)


   Cash (used in) provided by operating activities

(7)

132


CASH FLOWS FROM INVESTING ACTIVITIES:

Payments received on notes receivable from fixed asset sales

4

44

Purchase of property, plant and equipment

(27)

(17)


Cash (used in) provided by investing activities

(23)

27


CASH FLOWS FROM FINANCING ACTIVITIES:

Equity issuance costs

(3)

(2)


Cash (used in) financing activities

(3)

(2)

Net (decrease)/increase in cash, cash equivalents and restricted cash

(33)

157

Cash, cash equivalents and restricted cash, beginning of period

3,203

2,264

Cash, cash equivalents and restricted cash, end of period

$               3,170

$               2,421


SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION


CASH PAID FOR:

Interest

$                      –

$                      2

Income taxes

$                     7

$                      1

Non-cash activities:

Conversion of notes to common shares

$                      –

$                    64

Operating lease right of use assets at adoption

$                      –

$               3,428

Operating lease liability at adoption

$                      –

$               3,875

 


RAVE RESTAURANT GROUP, INC.


ADJUSTED EBITDA



(In thousands)


Three Months Ended


September 27,


September 29,


2020


2019

 Net income 

$                  76

$                237

 Interest expense 

23

27

 Income taxes 

2

73

 Depreciation and amortization 

44

47

 EBITDA 

$                145

$                384

 Gain on sale/disposal of assets 

–

(11)

 Impairment of long-lived assets and other lease charges

17

148

 Franchisee default and closed store revenue 

(67)

(147)

 Closed and non-operating store costs 

82

6

 Adjusted EBITDA 

$                177

$                380

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rave-restaurant-group-inc-reports-first-quarter-financial-results-301172999.html

SOURCE RAVE Restaurant Group, Inc.

Posted on

Mullen Group Ltd. 2021 Business Plan Conference Call and Webcast

PR Newswire

OKOTOKS, AB, Nov. 13, 2020 /PRNewswire/ – (TSX: MTL)  Mullen Group Ltd. (“Mullen Group” and/or the “Corporation“) intends to release its 2021 Business Plan after market close on Wednesday, December 9, 2020, and has scheduled a conference call and webcast as follows:


Date:                                 


December 10, 2020


Time:                                


11:00 a.m. ET


Conference Call Dial-in:     


1-800-319-4610 (for participants in North America)


416-915-3239 (Toronto or Overseas participants)


Webcast:                           



www.mullen-group.com

A replay of the call will be available approximately two hours after the completion of the call until Thursday, December 24, 2020, by dialing 1-800-319-6413 or 604-638-9010, access code 5651 followed by the pound sign.

About Mullen Group Ltd.

Mullen Group is a company that owns a network of independently operated businesses.  The Corporation is recognized as one of the leading suppliers of trucking and logistics services in Canada providing a wide range of service offerings including less-than-truckload, truckload, warehousing, logistics, transload, oversized and specialized hauling transportation.  In addition, we provide a diverse set of specialized services related to the energy, mining, forestry and construction industries in western Canada, including water management, fluid hauling and environmental reclamation.  The corporate office provides the capital and financial expertise, legal support, technology and systems support, shared services and strategic planning to its independent businesses.

Mullen Group is a publicly traded corporation listed on the Toronto Stock Exchange under the symbol “MTL“.  Additional information is available on our website at www.mullen-group.com or on SEDAR at www.sedar.com.

Contact Information

Mr. Murray K. Mullen – Chairman of the Board, Chief Executive Officer and President
Mr. P. Stephen Clark – Chief Financial Officer
Mr. Richard J. Maloney – Senior Vice President
Ms. Joanna K. Scott – Corporate Secretary & Vice President, Corporate Services

121A – 31 Southridge Drive
Okotoks, Alberta, Canada  T1S 2N3
Telephone:  403-995-5200
Fax:  403-995-5296

Cision View original content:http://www.prnewswire.com/news-releases/mullen-group-ltd-2021-business-plan-conference-call-and-webcast-301172996.html

SOURCE Mullen Group Ltd.

Posted on

Chembio Diagnostics Receives ANVISA Approval for DPP SARS-CoV-2 Antigen Test System in Brazil

HAUPPAUGE, N.Y., Nov. 13, 2020 (GLOBE NEWSWIRE) — Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced that its subsidiary Chembio Diagnostics Brazil Ltda. has received regulatory approval from Agência Nacional de Vigilância Sanitária (ANVISA) to market the DPP SARS-CoV-2 Antigen test system in Brazil.

The DPP SARS-CoV-2 Antigen test system is designed to detect SARS-CoV-2 antigens in only 20 minutes. The detection of specific SARS-CoV-2 viral antigens implies a current infection by the virus responsible for COVID-19 cases. The DPP SARS-CoV-2 Antigen test system consists of a DPP SARS-CoV-2 Antigen test cartridge, a DPP Micro Reader 1 or DPP Micro Reader 2 analyzer, and a minimally invasive nasal swab.

Clinical trial data demonstrates sensitivity of 96.0% at zero to six days from the onset of symptoms and specificity of 98.7% on symptomatic population as compared to PCR tests.

“We are grateful for the rapid review and approval of our DPP SARS-CoV-2 Antigen assay by ANVISA. The exceptional performance of this assay highlights again the value and flexibility of our DPP technology,” stated Javan Esfandiari, Chembio’s Vice President and Chief Science & Technology Officer. “We believe helping people understand their infection status has shown to be one of the most effective methods for controlling the spread of COVID-19. Enabling patients and providers to know this information at the point-of-care in 20 minutes can help further reduce the risk of virus transmission and improve patient outcomes. We are very proud to offer this test in Brazil and assist in efforts to manage the global pandemic.”

Chembio Diagnostics Brazil, formerly Orangelife Comercio e Industria Ltda., is Chembio’s Brazilian commercial subsidiary that Chembio acquired in November 2019. Offering leading point-of-care tests to Brazilian state, private, and pharmacy markets, Chembio Diagnostics Brazil also provides local support to the Company’s long-time partner Bio-Manguinhos.

“Combined with ANVISA’s prior Approval for Emergency Use of the DPP COVID-19 IgM/IgG assay, we are now able to offer the Brazilian healthcare system tests that detect active infections and provide antibody status that both run on the same Micro Reader analyzers. Our test systems are rapid, accurate, and ideal for decentralized testing which can help expand access to testing across communities,” stated Charles Caso, Chembio’s Vice President, Sales and Marketing. “We view Brazil as one of the most attractive infectious disease testing markets in the world, and we plan to expand the commercial team at Chembio Diagnostics Brazil to leverage our growing portfolio of approved tests in the country.”

About the DPP Rapid Test Platform

Chembio’s proprietary DPP technology platform provides high-quality, rapid diagnostic results in 15 to 20 minutes using a small drop of blood from the fingertip or alternative samples. Through advanced multiplexing, the DPP platform can detect up to eight, distinct test results from a single patient sample, delivering greater clinical value than other rapid tests. For certain applications, Chembio’s easy-to-use, highly portable, battery-operated DPP Micro Reader optical analyzer then reports accurate results in approximately 15 seconds, making it well-suited for decentralized testing where real-time results enable patients to be clinically assessed while they are still on-site. Objective results produced by the DPP Micro Reader reduce the possibility of the types of human error that can be experienced in the visual interpretations required by many rapid tests.

Chembio’s portfolio of DPP-based point-of-care tests with FDA regulatory approvals include the DPP HIV-Syphilis System (PMA approved), DPP HIV 1/2 Assay (PMA approved and CLIA waived), DPP Zika IgM System (510(k)), and DPP Ebola Antigen System (EUA). Additionally, DPP-based tests have received regulatory approvals from the World Health Organization, CE-Mark, Agência Nacional de Vigilância Sanitária (ANVISA), and other global organizations, where they aid in the detection and diagnosis of several other critical diseases and conditions.

All DPP tests are developed and manufactured in the United States and are the subject of a range of domestic and global patents and patents pending.

About Chembio Diagnostics

Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.

DPP is Chembio’s registered trademark. For convenience, this trademark appears in this release without ® symbols, but that practice does not mean that Chembio will not assert, to the fullest extent under applicable law, its rights to the trademark.

Contact:  
Philip Taylor
Gilmartin Group
(415) 937-5406
[email protected]



Posted on

Eurofins Transplant Diagnostics Introduces TruGraf Liver At AASLD – The Liver Meeting

Novel Biomarker-Based Assay Confirms Immune Quiescence in Liver Transplant Patients

PR Newswire

MANSFIELD, Mass., Nov. 13, 2020 /PRNewswire/ — Transplant Genomics, Inc. (“TGI”) a member of Eurofins Transplant Diagnostics, is excited to introduce TruGraf Liver, the only non-invasive blood-based test to assist in lowering immunosuppression in liver transplant patients, at The Liver Meeting Digital Experience (“The Liver Meeting”). The Liver Meeting is the annual meeting of the American Association for the Study of Liver Diseases, being held online November 13-16, 2020.  In continuation of Eurofins Transplant’s commitment to improving organ transplant outcomes worldwide, TruGraf Liver follows TruGraf®, the only non-invasive kidney rejection test reimbursed by CMS for the surveillance of “silent” sub-clinical acute rejection in patients with stable renal function.

TruGraf Liver is the only non-invasive blood-based test to assist in lowering immunosuppression in transplant patients.

Immunosuppression is essential to prevent rejection following liver transplantation. However, due to the significant complications associated with the use of immunosuppression, clinicians routinely minimize immunosuppression in liver transplant recipients in an effort to address these complications. TruGraf Liver is the first and only blood-based test that offers biomarker guidance to aid physicians in minimizing immunosuppression in transplant recipients. Until now, immunosuppression minimization has largely been a “trial and error” process, with clinicians relying only on laboratory and clinical indicators of rejection, graft injury, and failure resulting from the effects of immune activation. TruGraf Liver can help clinicians confirm immune quiescence prior to, as well as following, immunosuppression reduction in patients with stable graft function, minimizing the risk of overt graft injury due to rejection.

Josh Levitsky, MD, MS (Professor of Medicine and Surgery in the Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois) detailed the development of TruGraf Liver in his April 2020 article in the American Journal of Transplantation (https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15953). This study is based on findings from an NIH-funded, multi-center longitudinal study (CTOT-14: NCT01672164) that has set the stage for the use of non-invasive biomarkers for serial monitoring of liver transplant recipients. He will present his study at The Liver Meeting on Sunday, November 15 at 1:00pm ET, in a satellite symposium titled “Biomarkers in Liver Transplantation: The Next Frontier.”

Transplant Genomics is currently selecting liver transplant centers for the TruGraf Liver Early Access Program, and is preparing documentation for submission to the Molecular Diagnostics Services (MolDX) program to determine reimbursement coverage from the Centers for Medicare and Medicaid Services. The Early Access Program will be followed by the TRULI (TruGraf Liver) Registry Study, which is expected to involve more than 30 liver transplant centers and enroll up to 1,000 patients.

Members of the American Association for the Study of Liver Diseases may register for The Liver Meeting 2020 to see Dr. Levitsky’s presentation at https://www.aasld.org/node/2046.

Hepatologists and other liver transplant care professionals may contact Transplant Genomics to learn more about TruGraf Liver at (844) 878-4723 or at [email protected].

For more information:

Branden Morris

Transplant Genomics, Inc.
e) [email protected]
p) 510-745-4707

About Transplant Genomics, Inc.
Transplant Genomics, Inc. (“TGI”) is a personalized diagnostics company committed to improving organ transplant outcomes worldwide through innovative tests that detect early signs of graft injury, differentiate among actionable causes, and enable the optimization of therapy. Working alongside the transplant community and within the Eurofins family, TGI is commercializing a suite of tests enabling diagnoses and prediction of transplant recipient immune status. Our flagship product is TruGraf, the only blood test approved by CMS for surveillance and to rule out “silent” subclinical acute rejection in kidney transplant recipients with stable graft function. Test services are offered through TGI’s CLIA laboratory in Fremont, CA. TGI was acquired by Eurofins Scientific in 2019.

Learn more about Transplant Genomics at http://www.trugraf.com.

About Eurofins Scientific
Eurofins Scientific, through its subsidiaries (hereinafter “Eurofins” or “the Group”), believes it is the global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric and molecular clinical diagnostic testing. With over 50,000 staff across a network of more than 900 independent companies in over 50 countries generally specialised by end client markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services. The Group’s objective is to provide its customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly-qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.

As one of the most innovative and quality-oriented international groups in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Learn more about Eurofins at https://www.eurofins.com.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/eurofins-transplant-diagnostics-introduces-trugraf-liver-at-aasld–the-liver-meeting-301172995.html

SOURCE Transplant Genomics, Inc.

Posted on

Merck KGaA, Darmstadt, Germany, to present at the dbVIC – Deutsche Bank ADR Virtual Investor Conference on 19 November 2020

Merck KGaA invites individual and institutional investors, as well as advisors, to attend interactive, real-time virtual event

PR Newswire

DARMSTADT, Germany, Nov. 13, 2020 /PRNewswire/ — Merck KGaA, Darmstadt, Germany (LOCAL EXCHANGE: Deutsche Börse, US EXCHANGE: OTC), a leading science and technology company, today announced that Merck KGaA, Darmstadt, Investor Relations Director llja Doering will present at the dbVIC – Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference on November 19.  This virtual investor conference is aimed exclusively at introducing global companies with ADR programs to investors.

DATE: November 19, 2020
TIME: 11:00 – 11:30 AM ET
LINK: https://bit.ly/3jNDfgr

This will be a live, interactive online event where investors are invited to ask the company questions in real-time – both in the presentation hall as well as the organization’s “virtual trade booth.” If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.


Participation is free of charge.

Recent Company Highlights in Q3 2020:

  • Healthcare: Mavenclad® up 72% organically YoY after dip in Q2, Oncology up 7% strongly supported by early U.S. Bavencio® 1L UC ramp-up; sequential recovery of Fertility back to pre COVID-19 levels
  • Life Science: Process Solutions up 27% organically, strong rebound in Research Solutions with 10% organic growth, Applied Solutions recovery slower with 4% organic growth
  • Performance Materials: Semiconductor Solutions’ organic growth mitigates Display and Surface decline in pandemic; Versum performance & integration ahead of plan
  • Group: New ESG-targets – enhanced sustainability strategy leverages strengths and manifests company’s commitment

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 57,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals and OLEDs for smartphones and televisions. In 2019, Merck KGaA, Darmstadt, Germany, generated sales of € 16.2 billion in 66 countries.

About Virtual Investor ConferencesSM

Virtual Investor Conferences is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.

A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group’s suite of investor relations services specifically designed for more efficient Investor Access.  Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

Cision View original content:http://www.prnewswire.com/news-releases/merck-kgaa-darmstadt-germany-to-present-at-the-dbvic—deutsche-bank-adr-virtual-investor-conference-on-19-november-2020-301172994.html

SOURCE dbVIC – Deutsche Bank Depositary Receipts Virtual Investor Conference